Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Fineline Cube Dec 18, 2025
Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Fineline Cube Dec 18, 2025
Policy / Regulatory

Chinese Pharmacists Association Releases Draft VBP Drug Management Guidelines for Public Feedback

Fineline Cube Jul 26, 2022

The Chinese Pharmacists Association (CPA) has released the “National Volume-based Procurement (VBP) Drug Management Expert...

Company Deals

3D Medicines Files IPO Prospectus for Hong Kong Listing

Fineline Cube Jul 26, 2022

China-based oncology specialist 3D Medicines has published its initial public offering (IPO) prospectus with the...

Company Drug

I-Mab Doses First Patient in Global Phase I Study for TJ-CD4B in Solid Tumors

Fineline Cube Jul 25, 2022

I-Mab (NASDAQ: IMAB), a Nasdaq-listed company since 2020, announced that the first patient has been...

Company Deals Drug

Rona Therapeutics Licenses Sanofi’s siRNA Platform for Global Development

Fineline Cube Jul 25, 2022

Shanghai-based RNA therapeutics specialist Rona Therapeutics has entered into a licensing agreement with French pharmaceutical...

Company Digital

ApolloBio Corp. Initiates Pre-Clinical Study for ABC-5100 Nanobody Against COVID-19

Fineline Cube Jul 25, 2022

ApolloBio Corp. (NEEQ:430187) announced the initiation of a pre-clinical study for its novel broad-spectrum anti-COVID-19...

Company Deals

InventisBio Raises USD 308M in Shanghai STAR IPO, Valued at USD 1.54B

Fineline Cube Jul 25, 2022

China-based biotech firm InventisBio (SHA: 688382) has completed an initial public offering (IPO) of 115...

Policy / Regulatory

NMPA Releases 56th Batch of GQCE Reference Drugs, Including 14 Injectables

Fineline Cube Jul 25, 2022

The National Medical Products Administration (NMPA) has released the 56th batch of reference drugs for...

Company Deals

MobiDrop Raises USD 14.8M in Series A+ to Expand Single-Cell Product Pipeline

Fineline Cube Jul 25, 2022

China-based MobiDrop (Zhejiang) Co., Ltd has reportedly raised close to RMB 100 million (USD 14.8...

Company Drug

Luye Pharma’s LY01005 Meets Phase III Trial Goals in Breast Cancer Treatment

Fineline Cube Jul 25, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for LY01005...

Company Deals

ZGC Shuimu Medtech Raises RMB 100M in Series A+ Round Led by Yijing Capital

Fineline Cube Jul 25, 2022

Beijing-based ZGC Shuimu Medical Technology Services Group, China’s first private third-party medical device testing institution,...

Company Deals

Innovita Biological Technology’s IPO Raises USD 131.3M for POCT Expansion

Fineline Cube Jul 25, 2022

Innovita Biological Technology Co., Ltd, a Beijing-based point-of-care testing (POCT) specialist, is set to make...

Company Drug

Fidia Farmaceutici’s Hyalubrix 60 Shows Promise in Treating Arthropathy at Hainan Hospital

Fineline Cube Jul 25, 2022

Italy-based Fidia Farmaceutici S.p.A announced that its Hyalubrix 60, a prefilled syringe with sodium hyaluronate...

Company Deals

Linno Pharmaceuticals Raises USD 14.78M for Blood-Brain Barrier Drug Delivery Tech

Fineline Cube Jul 22, 2022

Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million...

Company Deals

Frontier Biotech Raises USD 51.4M to Advance COVID-19 Drug FB2001

Fineline Cube Jul 22, 2022

China-based Frontier Biotechnologies Inc. (SHA: 688221) announced plans to raise RMB 270 million (USD 51.4...

Company Deals

Curatia Medical Raises Tens of Millions in Funding Co-led by Hidea Investment

Fineline Cube Jul 22, 2022

Curatia Medical Ltd, a vascular interventional therapy developer with operations in Silicon Valley, California, and...

Company Deals

Novaremed AG Licenses NRD.E1 to NeuroFront for Greater China Development

Fineline Cube Jul 22, 2022

Switzerland-based Novaremed AG has entered into a licensing agreement with China’s NeuroFront (Shanghai) Co., Ltd,...

Drug

Ascentage Pharma’s Olverembatinib Receives Health Canada Approval for Phase Ib Study

Fineline Cube Jul 22, 2022

Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from Health Canada to...

Company Drug

Junshi Biosciences’ Toripalimab Receives EC Orphan Drug Designation for NPC

Fineline Cube Jul 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) announced that its PD-1 inhibitor Toripalimab (trade name:...

Company Deals

Yifeng Pharmacy Chain to Establish New Company with Tangshan Deshuntang

Fineline Cube Jul 22, 2022

China-based Yifeng Pharmacy Chain Co., Ltd (SHA: 603939) announced that its subsidiary, Shijiazhuang Xinxing Pharmacy...

Company Drug

Ji Xing Pharmaceuticals Enrolls First Patient in OC-01 Phase III Study for Dry Eye

Fineline Cube Jul 22, 2022

Shanghai-based Ji Xing Pharmaceuticals, backed by RTW Investments, announced that the first patient has been...

Posts pagination

1 … 579 580 581 … 599

Recent updates

  • Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
  • DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer
  • Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan
  • Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets
  • Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Company Drug

Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan

Company Drug

Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.